JSKN021 / Alphamab - LARVOL DELTA

Early-stage R&D:…Expected Milestones in 2025 (PRNewswire-Asia) - "(i) JSKN027: File an IND application with the CDE; (ii) JSKN021: File an application for a phase I clinical study in Australia."

New trial • Solid Tumor

JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities (AACR 2025) - "The preclinical studies suggest JSKN021, as a dual-payload EGFR/HER3 bispecific ADC, might be a promising novel antitumor therapeutic agent."

Preclinical • Oncology • EGFR • ERBB3